From NSCLC to Melanoma: Clinical Applications Driving the PD-L1...

ha aggiunto una foto Health

2026-08-06 14:55:36 - Translate -

From NSCLC to Melanoma: Clinical Applications Driving the PD-L1 Inhibitors Market

The clinical applications of PD-L1 inhibitors span diverse cancer types, from non-small cell lung cancer and melanoma to breast cancer and hepatocellular carcinoma. The PD-L1 Inhibitors Market is benefiting from this diverse demand, valued at USD 50.99 billion in 2024 and projected to reach USD 323.92 billion by 2035 at a CAGR of 18.3%. This article explores the clinical applications...

0 Commenti 0 condivisioni 2 Views 0 Anteprima